| Market Cap | 1.22B | P/E | - | EPS this Y | 67.90% | Ern Qtrly Grth | - |
| Income | -100.44M | Forward P/E | -19.08 | EPS next Y | 1.30% | 50D Avg Chg | -5.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 15.00% |
| Dividend | N/A | Price/Book | 5.16 | EPS next 5Y | - | 52W High Chg | -25.00% |
| Recommedations | 1.70 | Quick Ratio | 40.92 | Shares Outstanding | 57.20M | 52W Low Chg | 53.00% |
| Insider Own | 4.84% | ROA | -13.01% | Shares Float | 162.30M | Beta | - |
| Inst Own | 107.55% | ROE | -17.69% | Shares Shorted/Prior | 10.56M/11.20M | Price | 31.86 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 205,693 | Target Price | 87.90 |
| Oper. Margin | - | Earnings Date | - | Volume | 1,808,564 | Change | -12.52% |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.